Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
3(21%)
Results Posted
38%(3 trials)
Terminated
1(7%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_4
3
21%
Ph phase_2
6
43%
Ph phase_3
4
29%

Phase Distribution

0

Early Stage

6

Mid Stage

7

Late Stage

Phase Distribution14 total trials
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
4(28.6%)
Phase 4Post-market surveillance
3(21.4%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

3

trials recruiting

Total Trials

14

all time

Status Distribution
Active(3)
Completed(8)
Terminated(1)
Other(2)

Detailed Status

Completed8
Recruiting2
unknown2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
3
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 26 (42.9%)
Phase 34 (28.6%)
Phase 43 (21.4%)
N/A1 (7.1%)

Trials by Status

recruiting214%
completed857%
active_not_recruiting17%
terminated17%
unknown214%

Recent Activity

3 active trials
Showing 5 of 14
recruitingphase_2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

NCT06016634
active_not_recruitingphase_4

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

NCT05493761
terminatedphase_2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
unknownphase_2

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

NCT05397938
recruitingphase_3

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

NCT04704947
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT06016634Phase 2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Recruiting
NCT05493761Phase 4

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Active Not Recruiting
NCT00019695Phase 2

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Terminated
NCT05397938Phase 2

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Unknown
NCT04704947Phase 3

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Recruiting
NCT00354302Phase 3

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Completed
NCT02795546Phase 4

Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.

Completed
NCT00996801Phase 2

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Completed
NCT00004489Not Applicable

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

Completed
NCT00004488Phase 2

Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease

Completed
NCT00504166Phase 4

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

Completed
NCT00122356Phase 3

Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment

Completed
NCT00051558Phase 3

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Completed
NCT00209469Phase 2

Network Osteoporosis Study

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14